Rare Mutations and Fusions Patient Gateway
About rare mutations and fusions in lung cancer
Currently, there are nine DNA-based alterations, or biomarkers, for which we have targeted therapies in NSCLC. Rare mutations and fusions include BRAF V600E, MET, NTRK, RET and ROS1.
LATEST UPDATES
-
Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer
As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx... -
What the End of the COVID Public Health Emergency Means for You
It’s been more than 3 years since the US Department of Health and Human Services (HHS) first declared a nationwide Public Health Emergency (PHE) due to COVID-19. Since then... -
Tackling the Biggest Challenges in Cancer
Cancer Grand Challenges is a partnership between Cancer Research UK (CRUK) and the National Cancer Institute (NCI), which funds global teams of leading researchers across various...
Sponsors
